Abdul-Mutakabbir, J.C.; Kebriaei, R.; Stamper, K.C.; Sheikh, Z.; Maassen, P.T.; Lev, K.L.; Rybak, M.J.
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model. Antibiotics 2020, 9, 696.
https://doi.org/10.3390/antibiotics9100696
AMA Style
Abdul-Mutakabbir JC, Kebriaei R, Stamper KC, Sheikh Z, Maassen PT, Lev KL, Rybak MJ.
Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model. Antibiotics. 2020; 9(10):696.
https://doi.org/10.3390/antibiotics9100696
Chicago/Turabian Style
Abdul-Mutakabbir, Jacinda C., Razieh Kebriaei, Kyle C. Stamper, Zain Sheikh, Philip T. Maassen, Katherine L. Lev, and Michael J. Rybak.
2020. "Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model" Antibiotics 9, no. 10: 696.
https://doi.org/10.3390/antibiotics9100696
APA Style
Abdul-Mutakabbir, J. C., Kebriaei, R., Stamper, K. C., Sheikh, Z., Maassen, P. T., Lev, K. L., & Rybak, M. J.
(2020). Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model. Antibiotics, 9(10), 696.
https://doi.org/10.3390/antibiotics9100696
